Clinical observation of Brucea javanica oil emulsion injection combined with S-1 for treatment of elderly patients with advanced gastric cancer
10.3760/cma.j.issn.1006-9801.2019.11.003
- VernacularTitle: 鸦胆子油乳注射液联合替吉奥治疗老年人晚期胃癌的临床观察
- Author:
Rongfang WU
1
;
Gehong ZHANG
1
;
Baozhen ZHENG
2
Author Information
1. Department of Oncology, the First Hospital of Shanxi Medical University, Taiyuan 030001, China
2. Department of Thoracic Radiotherapy 1, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Aged;
S-1;
Brucea javanica oil injection;
Treatment outcome;
Adverse reactions
- From:
Cancer Research and Clinic
2019;31(11):729-733
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy and safety of Brucea javanica oil injection combined with S-1 in the treatment of elderly patients with advanced gastric cancer.
Methods:The clinical data of 62 elderly patients with advanced gastric cancer who were admitted to Shanxi Provincial Cancer Hospital from May 2017 to May 2018 were retrospectively analyzed. Thirty-one patients in the control group treated with S-1 alone, and 31 patients in the observation group treated with S-1 combined with Brucea oil emulsion injection. The clinical efficacy, adverse reactions, immune function and quality of life of the two groups were compared.
Results:The total effective rates of the observation group and the control group were 70.97% (22/31) and 48.39% (15/31), respectively, and the difference was statistically significant (χ 2 = 11.889, P < 0.01). The incidence rates of gastrointestinal reaction and peripheral neurotoxicity in the observation group were 9.68% (3/31) and 3.23% (1/31), and the rates in the control group were 35.48% (11/31) and 25.81% (8/31), respectively, the differences between the two groups were statistically significant (both P < 0.05); the incidence rates of hepatotoxicity, nephrotoxicity and myelosuppression in the observation group were 3.23% (1/31), 3.23% (1/31), and 3.23% (1/31), and the rates in the control group were 22.58% (7/31), 16.13% (5/31), and 12.90% (4/31), respectively, and the differences between the two groups were not statistically significant (all P > 0.05). The Karnofsky scores of the observation group and the control group after treatment were (92±4) points and (86±3) points, respectively, and the difference was statistically significant (t = -2.075, P = 0.042). The serum levels of interleukin-2 (IL-2) and interferon-γ in the observation group after treatment were (38±4) ng/L and (51±4) ng/L, and the levels in the control group were (31±3) ng/L and (40±4) ng/L, respectively, and the differences were statistically significant (t values were -2.097 and -2.293, both P < 0.05), and the serum levels of IL-4, IL-6 and IL-10 in the observation group after treatment were (42±5) ng/L, (34±4) ng/L and (22±2) ng/L, and the levels in the control group were (59±6) ng/L, (50±5) ng/L and (30±3) ng/L, respectively, and the differences were statistically significant (t values were 2.109, 2.867 and 4.278, all P < 0.05). There was no statistical difference in the serum levels of tumor necrosis factor-α between the observation group and the control group after treatment (t = -0.922, P = 0.360).
Conclusion:Compared with monotherapy of S-1, the treatment of Brucea javanica oil emulsion injection combined with S-1 can improve the clinical efficacy, reduce the incidence of adverse reactions, enhance the immune function and effectively improve the quality of life of elderly patients with advanced gastric cancer.
